Online citations, reference lists, and bibliographies.
← Back to Search

Atezolizumab (A) + Cobimetinib (C) + Vemurafenib (V) In BRAFV600-mutant Metastatic Melanoma (mel): Updated Safety And Clinical Activity.

R. Sullivan, René González, K. Lewis, O. Hamid, J. Infante, M. Patel, F. S. Hodi, Jeffrey Wallin, B. Pitcher, E. Cha, L. Roberts, M. Ballinger, P. Hwu
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
3063Background: Targeted inhibition of MEK with C and BRAF with V in BRAFV600-mutant mel can lead to both anticancer immune activation and direct tumor cell death. A, an anti–PD-L1 monoclonal antib...



This paper is referenced by
10.1080/14712598.2017.1378640
Immunotherapy in managing metastatic melanoma: which treatment when?
T. Amaral (2017)
10.1159/000478081
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
S. Hwang (2018)
10.1007/978-3-319-46029-1_61-1
Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma
P. Ascierto (2019)
10.1007/978-3-319-46029-1_40-1
Targeted Therapies for BRAF-mutant metastatic Melanoma
Douglas B. Johnson (2019)
10.1007/s10585-018-9913-y
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
Thein Swe (2018)
10.3390/cancers11040539
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
V. Longo (2019)
10.1007/978-981-13-0496-5_12
Translational Biomarkers: Application in the Clinical Development of Combination Therapies
S. Sukumar (2018)
10.1007/978-3-030-02505-2_1
Overview of Basic Immunology and Translational Relevance for Clinical Investigators.
B. Stephen (2018)
10.1111/jdv.15335
Dermatology today and tomorrow: from symptom control to targeted therapy
U. Blume-Peytavi (2019)
10.1001/jamaoncol.2018.2668
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials
A. Hauschild (2018)
10.1016/j.critrevonc.2018.11.002
Advanced stage melanoma therapies: Detailing the present and exploring the future.
C. Luther (2019)
BRAF: From Discovery to Drug Resistance
Mary Jo Pilat (2019)
10.1080/21678707.2019.1672534
Mucosal melanoma: current strategies and future directions
S. Khan (2019)
10.1007/s00262-018-2285-y
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
M. Maio (2018)
10.1007/s13555-019-0292-3
Beyond PD-1 Immunotherapy in Malignant Melanoma
Dominika Kwiatkowska (2019)
10.1080/14656566.2019.1601700
Current and emerging systemic therapies for cutaneous metastatic melanoma
R. Mason (2019)
10.1016/J.SOC.2019.02.001
Current Immunotherapy Practices in Melanoma.
Luke D Rothermel (2019)
10.1177/1758835919830826
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
M. S. Pelster (2019)
10.1097/PPO.0000000000000299
Clinical Development of PD-1 in Advanced Melanoma
R. Munhoz (2018)
10.2147/OTT.S171693
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
James Sun (2018)
10.1186/s12943-018-0800-6
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan (2018)
10.1016/j.ejphar.2019.172621
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
A. Rossi (2019)
10.3390/molecules22101551
Current Development Status of MEK Inhibitors
Ying Cheng (2017)
10.1080/17425255.2018.1432593
Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors
Elnaz Faghfuri (2018)
10.1080/21678707.2017.1399122
Mucosal melanoma: epidemiology, biology, management and the role of immunotherapy
S. Shen (2017)
10.1007/978-3-030-41008-7_1
Overview of Basic Immunology and Clinical Application.
Bettzy Stephen (2020)
10.1097/CCO.0000000000000466
Immunotherapy-based combinations: an update
G. Fucà (2018)
10.1038/s41388-018-0171-x
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
M. Dankner (2018)
10.1186/s12967-019-1979-z
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
P. Ascierto (2019)
10.1016/J.BULCAN.2018.04.011
Actualités autour des inhibiteurs de checkpoints immunitaires : enseignements issus du congrès ASCO 2017 et perspectives
M. Kfoury (2018)
10.5772/intechopen.86615
B-Raf-Mutated Melanoma
Sarah E. Fenton (2020)
10.1097/CCO.0000000000000709
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
C. Trojaniello (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar